# US 10,307,471 B2 · Immunity inducer for saccharide antigens

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,307,471 B2
- Document ID: US10307471B2
- Status: Granted
- Kind: B2
- Application number: 14/888,353
- Filed: 2014-05-02
- Published: 2016-03-17
- Granted: 2019-06-04
- Earliest claimed: 2013-05-02
- Assignees: National Institute of Advanced Industrial Science and Technology
- Applicants: National Institute of Advanced Industrial Science and Technology
- Inventors: Tetsuya Okuda; Hiroki Shimizu
- Web page: https://patentgrep.com/patent/US10307471B2

## CPC

- C08B 37/00: Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof (cellulose D21; {microbiological processes C12P})
- A61K 31/702: Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
- A61K 31/7028: Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K 39/001169: {Tumor associated carbohydrates}
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 47/543: {Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine}
- A61P 37/04: Immunostimulants
- C07H 15/06: being a hydroxyalkyl group esterified by a fatty acid
- C07H 15/10: containing unsaturated carbon-to-carbon bonds
- C07K 16/18: against material from animals or humans
- A61K 2039/55511: {Organic adjuvants}
- A61K 2039/6018: {Lipids, e.g. in lipopeptides}
- A61K 2039/627: {characterised by the linker}
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides an immunity inducer and an immunity inducing method using same. The immunity inducer has an immunopotentiation effect on any target oligosaccharide antigen, in particular oligosaccharide antigens included in mammal-derived glycoprotein N-linked sugar chains; is capable of providing a monoclonal antibody having high specificity to and affinity with target oligosaccharide antigens; and has as an effective component thereof a glycolipid including a target oligosaccharide antigen (R) and indicated by general formula (2), or a salt thereof. General formula (2): R—Z—Y—CH(NH—CO—(CH2)n1—CH3)—CH2)n2—CH3 (in the formula, R indicates a straight-chain or branched oligosaccharide comprising 2-30 of at least one type of monosaccharide. Z indicates a single bond, O, S or NH, a linker bound to thiomethyl, amino methylated sugar alcohol. Y indicates —(CH2)m—. n1 indicates an integer of 2-40, n2 indicates an integer of 1-27, and m indicates an integer of 1-30).

## Claims

### Claim 1

An immunity inducer comprising an artificial glycolipid or a salt thereof as an effective component, wherein the artificial glycolipid has the chemical formula (2) and includes the target oligosaccharide antigen R:
R—Z—Y—CH(NH—CO—(CH2)n1—CH3)—(CH2)n2—CH3 chemical formula (2)
wherein, in the chemical formula (2), R represents a linear chain or branched oligosaccharide constituted with 2 to 30 of one type or plural types of monosaccharides , Z represents a single bond, O, S or NH, a linker bound to thiomethyl, or an aminomethylated sugar alcohol, Y represents —(CH2)m—, n1 represents an integer from 2 to 40, n2 represents an integer from 1 to 27, and m represents an integer from 1 to 30, and
wherein the target oligosaccharide antigen R is selected from the group consisting of
an oligosaccharide antigen included in a mammal-derived glycoprotein N-linked sugar chain selected from the group consisting of Siaα2,6Galβ1,4GlcNAc, Siaα2,3Galβ1,4GlcNAc, Galβ1,4GlcNAc, Galβ1,3GlcNAc, Siaα2,3Galβ1,4(Fucα1,3)GlcNAc, Galβ1,4(Fucα1,3)GlcNAc, Siaα2,3Galβ1,3(Fucα1,4)GlcNAc, Siaα2,3Galβ1,3GlcNAc, Galβ1,3(Fucα1,4)GlcNAc, Siaα2,3Galβ1,3 (Siaα2,6)GlcNAc, Siaα2,3Galβ1,3 (Fucα1,4)(Siaα2,6)GlcNAc, Fucα1,2Galβ1,3(Fucα1,4)GlcNAc, Fucα1,2Galβ1,4GlcNAc, Fucα1,2Galβ1,4(Fucα1,3)GlcNAc, Fucα1,6GlcNAc, GlcNAcβ1,4(Fucα1,6)GlcNAc, Manβ1,4GlcNAcβ1,4(Fucα1,6)GlcNAc, Manα1,6(Manα1,3)Manβ1,4GlcNAcβ1,4(Fucα1,6)GlcNAc, Manα1,6(GlcNAcβ1,4) (Manα1,3)Manβ1,4GlcNAcβ1,4GlcNAc, Manα1,6(GlcNAcβ1,4) (Manα1,3)Manβ1,4GlcNAcβ1,4(Fucα1,6)GlcNAc, GlcNAcβ1,4GlcNAc, Manβ1,4GlcNAcβ1,4GlcNAc, GlcNAcβ1,2Man, GlcNAcβ1,4Man, GlcNAcβ1,6Man, Galβ1,3GlcNAcβ1,2Man, Galβ1,3GlcNAcβ1,4Man, Galβ1,3GlcNAcβ1,6Man, Galβ1,4GlcNAcβ1,2Man, Galβ1,4GlcNAcβ1,4Man, Galβ1,4GlcNAcβ1,6Man, Siaα2,3Galβ1,4GlcNAcβ1,2Man, Siaα2,3Galβ1,4GlcNAcβ1,4Man, Siaα2,3Galβ1,4GlcNAcβ1,6Man, Siaα2,3Galβ1,3GlcNAcβ1,2Man, Siaα2,3Galβ1,3GlcNAcβ1,4Man, Siaα2,3Galβ1,3GlcNAcβ1,6Man, Siaα2,6Galβ1,4GlcNAcβ1,2Man, Siaα2,6Galβ1,4GlcNAcβ1,4Man, Siaα2,6Galβ1,4GlcNAcβ1,6Man, GalNAcβ1,4GlcNAc, GalNAcβ1,4GlcNAcβ1,2Man, GalNAc(4SO4)β1,4GlcNAc, GalNAc(4SO4)β1,4GlcNAcβ1,2Man, GalNAc(4SO4)β1,4GlcNAcβ1,4Man, GalNAc(4SO4)β1,4GlcNAcβ1,6Man, GlcAβ1,3Galβ1,4GlcNAc, GlcA(3SO4)β1,3Galβ1,4GlcNAc, Siaα2,3Galβ1,4(Fucα1,3)GlcNAc(6 SO4), Siaα2,3Galβ1,4GlcNAc(6SO4), Galβ1,4GlcNAc(6SO4), Galβ1,4(Fucα1,3) GlcNAc(6SO4), Siaα2,3Gal(6SO4)β1,4 (Fucα1,3)GlcNAc, Siaα2,3Gal(6SO4)β1,4GlcNAc, Gal(6SO4)β1,4GlcNAc, Gal(6SO4)β1,4GlcNAc(6SO4), Galβ1,4GlcNAcβ1,3Gal, GlcNAcβ1,3Galβ1,4GlcNAc, Galβ1,4GlcNAc(6SO4)β1,3Gal, GlcNAc(6SO4)β1,3Galβ1,4GlcNAc, Gal(6SO4)β1,4GlcNAc(6SO4)β1,3Gal, GlcNAc(6SO4)β1,3Gal(6SO4)β1,4GlcNAc, Siaα2,3Galβ1,4GlcNAcβ1,3Galβ1,4(Fucα1,3)GlcNAc, Fucα1,2Galβ1,3GlcNAc, Galα1,3(Fucα1,2)Galβ1,3GlcNAc, Galα1,3(Fucα1,2)Galβ1,4GlcNAc, GalNAcα1,3(Fucα1,2)Galβ1,3GlcNAc, GalNAcα1,3(Fucα1,2)Galβ1,4GlcNAc, Fucα1,2Galβ1,4(Fucα1,3)GlcNAcβ1,3Gal, Gal(3SO4)β1,4GlcNAc, Gal(3SO4)β1,4(Fucα1,3)GlcNAc, Gal(3SO4)β1,3GlcNAc, Gal(3SO4)β1,3(Fucα1,4)GlcNAc, Gal(3SO4)β1,4GlcNAc(6SO4), Gal(3SO4)β1,4(Fucα1,3)GlcNAc(6SO4), Siaα2,8Siaα2,8Sia, Siaα2,6GalNAcβ1,4GlcNAc, Siaα2,3Galβ1,4(Fucα1,3)GlcNAcβ1,3Galβ1,4(Fucα1,3)GlcNAc, Galβ1,4GlcNAcβ1,3(Galβ1,4GlcNAcβ1,6)Gal, and Siaα2,3Galβ1,4GlcNAcβ1,3(Siaα2,3Galβ1,4GlcNAcβ1,6)Gal,
an oligosaccharide antigen included in a mammal-derived glycoprotein O-linked sugar chain selected from the group consisting of Siaα2,3Galβ1,3GalNAc, Galβ1,3GalNAc, Siaα2,3Galβ1,3(GlcNAcβ1,6)GalNAc, GalNAcα1,3GalNAc, GlcNAcβ1,3(Siaα2,6)GalNAc, GalNAcα1,6GalNAc, GlcNAcβ1,6GalNAc, Fucα1,2GalNAc, Galβ1,3(GlcNAcβ1,6)GalNAc, Siaα2,6GalNAc, Siaα2,6(GlcNAcβ1,6)GalNAc, Siaα2,3Galβ1,3(Siaα2,6)GalNAc, Galβ1,4GalNAc, Siaα2,3Galβ1,4GalNAc, GlcNAcα1,4Gal, GlcNAcα1,4Galβ1,4GlcNAc, GlcNAcα1,4Galβ1,4GalNAc, GlcNAcα1,4Galβ1,4(GlcNAcα1,4Galβ1,4GlcNAcβ1,6)GalNAc, Siaα2,3Galβ1,4(Fucα1,3)GlcNAc(6SO4)β1,6GalNAc, Gal(3SO4)β1,4GlcNAcβ1,6(Siaα2,3Galβ1,3)GalNAc, Siaα2,3Galβ1,4(Fucα1,3)GlcNAc(6SO4)β1,3Galβ1,3GalNAc, Siaα2,3Galβ1,4(Fucα1,3)GlcNAc(6SO4)β1,3Galβ1,3(Siaα2,3Galβ1,4(Fucα1,3)GlcNAc(6SO4)β1,6)GalNAc, Siaα2,3Gal(6SO4) β1,4GlcNAcβ1,3Galβ1,3GalNAc, Gal(3SO4)β1,3GalNAc(6SO4), Siaα2,3Galβ1,3GalNAc(6SO4), Gal(3SO4)β1,3(Siaα2,6)GalNAc, and Gal(3SO4)β1,3GalNAc, and
an oligosaccharide antigen included in a mammal-derived glycosaminoglycan type sugar chain selected from the group consisting of Galβ1,4Xyl, Galβ1,3Galβ1,4Xyl, GlcAβ1,3Galβ1,3Galβ1,4Xyl, GalNAcβ1,4IdoAα1,3Galβ1,3Galβ1,4Xyl, GalNAcβ1,4GlcAβ1,3Galβ1,3Galβ1,4Xyl, GlcNAcα1,4GlcAβ1,3Galβ1,3Galβ1,4Xyl, GlcAβ1,3GalNAcβ1,4GlcA, GalNAcβ1,4GlcAβ1,3GalNAc, GlcAβ1,3GalNAc(4SO4)β1,4GlcA, GalNAc(4SO4)β1,4GlcAβ1,3GalNAc, GlcAβ1,3GalNAc(6SO4)β1,4GlcA, GalNAc(6SO4)β1,4GlcAβ1,3GalNAc, GlcA(2SO4)β1,3(6SO4)GalNAcβ1,4GlcA, GalNAc(6SO4)β1,4GlcA(2SO4)β1,3GalNAc, GlcAβ1,3GalNAc(4,6SO4)β1,4GlcA, GalNAc(4,6SO4)β1,4GlcAβ1,3GalNAc, GalNAc(4,6SO4)β1,4GlcA(2SO4)β1,3GalNAc(6SO4), IdoAα1,3GalNAcβ1,4IdoA, GalNAcβ1,4IdoAα1,3GalNAc, IdoAα1,3GalNAc(4SO4)β1,4IdoA, GalNAc(4SO4)β1,4IdoAα1,3GalNAc, GlcAβ1,4GlcNAcα1,4GlcA, GlcNAcα1,4GlcAβ1,4GlcNAc, GlcA(2SO4)β1,4GlcNAcα1,4GlcA, GlcNAcα1,4GlcA(2SO4)β1,4GlcNAc, IdoA(2SO4)α1,4GlcNAcα1,4GlcA, GlcNAcα1,4IdoA(2SO4)α1,4GlcNAc, GlcA(2SO4)β1,4GlcNSO3α1,4GlcA, GlcNSO3α1,4GlcA(2SO4)β1,4GlcNAc, IdoA(2SO4)α1,4GlcNSO3Hα1,4GlcA, GlcNSO3α1,4IdoA(2SO4)α1,4GlcNAc, GlcAβ1,4GlcNα1,4GlcA, GlcAβ1,4GlcNSO3α1,4GlcA, GlcNSO3α1,4GlcAβ1,4GlcNAc, IdoAα1,4GlcNSO3α1,4GlcA, GlcNSO3α1,4IdoAα1,4GlcNAc, GlcAβ1,4GlcNSO3(6SO4)α1,4GlcA, GlcNSO3(6SO4)α1,4GlcAβ1,4GlcNAc, IdoAα1,4GlcNSO3(6SO4)α1,4GlcA, GlcNSO3(6SO4)α1,4IdoAα1,4GlcNAc, IdoA(2SO4)α1,4GlcNSO3(6SO4)α1,4GlcA, GlcNSO3(6SO4)α1,4IdoA(2SO4)α1,4GlcNAc, IdoAα1,4GlcNSO3α1,4IdoA, GlcAβ1,3GlcNAcβ1,4GlcA, GlcNAcβ1,4GlcAβ1,3GlcNAc, IdoAα1,4GlcNSO3, IdoAα1,4GlcNSO3(6SO4), IdoA(2SO4)α1,4GlcNSO3, IdoA(2SO4)α1,4GlcNSO3(6SO4), IdoA(2SO4)α1,4GlcNSO3(3SO4), GlcAβ1,4GlcNSO3, GlcAβ1,4GlcNSO3(6SO4), GlcA(2SO4)β1,4GlcNAc, GlcA(2SO4)β1,4GlcNSO3(3SO4), GlcAβ1,4GlcNSO3(3,6SO4), and GlcAβ1,4GlcNSO3(3SO4).

### Claim 2 (depends on 1)

The immunity inducer according to claim 1, wherein the target oligosaccharide antigen R is an oligosaccharide antigen included in a mammal-derived glycoprotein N-linked sugar chain selected from the group consisting of Siaα2,6Galβ1,4GlcNAc, Siaα2,3Galβ1,4GlcNAc, Galβ1,4GlcNAc, Galβ1,3GlcNAc, Siaα2,3Galβ1,4(Fucα1,3)GlcNAc, Galβ1,4 (Fucα1,3)GlcNAc, Siaα2,3Galβ1,3(Fucα1,4)GlcNAc, Siaα2,3Galβ1,3GlcNAc, Galβ1,3(Fucα1,4)GlcNAc, Siaα2,3Galβ1,3 (Siaα2,6)GlcNAc, Siaα2,3Galβ1,3(Fucα1,4)(Siaα2,6)GlcNAc, Fucα1,2Galβ1,3(Fucα1,4)GlcNAc, Fucα1,2Galβ1,4GlcNAc, Fucα1,2Galβ1,4(Fucα1,3)GlcNAc, Fucα1,6GlcNAc, GlcNAcβ1,4 (Fucα1,6)GlcNAc, Manβ1,4GlcNAcβ1,4(Fucα1,6)GlcNAc, Manα1,6(Manα1,3)Manβ1,4GlcNAcβ1,4(Fucα1,6)GlcNAc, Manα1,6(GlcNAcβ1,4) (Manα1,3)Manβ1,4GlcNAcβ1,4GlcNAc, Manα1,6 (GlcNAcβ1,4) (Manα1,3)Manβ1,4GlcNAcβ1,4(Fucα1,6)GlcNAc, GlcNAcβ1,4GlcNAc, Manβ1,4GlcNAcβ1,4GlcNAc, GlcNAcβ1,2Man, GlcNAcβ1,4Man, GlcNAcβ1,6Man, Galβ1,3GlcNAcβ1,2Man, Galβ1,3GlcNAcβ1,4Man, Galβ1,3GlcNAcβ1,6Man, Galβ1,4GlcNAcβ1,2Man, Galβ1,4GlcNAcβ1,4Man, Galβ1,4GlcNAcβ1,6Man, Siaα2,3Galβ1,4GlcNAcβ1,2Man, Siaα2,3Galβ1,4GlcNAcβ1,4Man, Siaα2,3Galβ1,4GlcNAcβ1,6Man, Siaα2,3Galβ1,3GlcNAcβ1,2Man, Siaα2,3Galβ1,3GlcNAcβ1,4Man, Siaα2,3Galβ1,3GlcNAcβ1,6Man, Siaα2,6Galβ1,4GlcNAcβ1,2Man, Siaα2,6Galβ1,4GlcNAcβ1,4Man, Siaα2,6Galβ1,4GlcNAcβ1,6Man, GalNAcβ1,4GlcNAc, GalNAcβ1,4GlcNAcβ1,2Man, GalNAc(4SO4)β1,4GlcNAc, GalNAc(4SO4)β1,4GlcNAcβ1,2Man, GalNAc(4SO4)β1,4GlcNAcβ1,4Man, GalNAc(4SO4)β1,4GlcNAcβ1,6Man, GlcAβ1,3Galβ1,4GlcNAc, GlcA(3SO4)β1,3Galβ1,4GlcNAc, Siaα2,3Galβ1,4 (Fucα1,3)GlcNAc(6SO4), Siaα2,3Galβ1,4GlcNAc(6SO4), Galβ1,4GlcNAc(6SO4), Galβ1,4(Fucα1,3) GlcNAc(6SO4), Siaα2,3Gal(6SO4)β1,4 (Fucα1,3)GlcNAc, Siaα2,3Gal(6SO4)β1,4GlcNAc, Gal(6SO4)β1,4GlcNAc, Gal(6SO4)β1,4GlcNAc(6SO4), Galβ1,4GlcNAcβ1,3Gal, GlcNAcβ1,3Galβ1,4GlcNAc, Galβ1,4GlcNAc(6SO4)β1,3Gal, GlcNAc(6SO4)β1,3Galβ1,4GlcNAc, Gal(6SO4)β1,4GlcNAc(6SO4)β1,3Gal, GlcNAc(6SO4)β1,3Gal(6SO4)β1,4GlcNAc, Siaα2,3Galβ1,4GlcNAcβ1,3Galβ1,4(Fucα1,3)GlcNAc, Fucα1,2Galβ1,3GlcNAc, Galα1,3(Fucα1,2)Galβ1,3GlcNAc, Galα1,3(Fucα1,2)Galβ1,4GlcNAc, GalNAcα1,3(Fucα1,2)Galβ1,3GlcNAc, GalNAcα1,3(Fucα1,2)Galβ1,4GlcNAc, Fucα1,2Galβ1,4(Fucα1,3)GlcNAcβ1,3Gal, Gal(3SO4)β1,4GlcNAc, Gal(3SO4)β1,4(Fucα1,3)GlcNAc, Gal(3SO4)β1,3GlcNAc, Gal(3SO4)β1,3(Fucα1,4)GlcNAc, Gal(3SO4)β1,4GlcNAc(6SO4), Gal(3SO4)β1,4(Fucα1,3)GlcNAc(6SO4), Siaα2,8Siaα2,8Sia, Siaα2,6GalNAcβ1,4GlcNAc, Siaα2,3Galβ1,4(Fucα1,3)GlcNAcβ1,3Galβ1,4(Fucα1,3)GlcNAc, Galβ1,4GlcNAcβ1,3(Galβ1,4GlcNAcβ1,6)Gal, and Siaα2,3Galβ1,4GlcNAcβ1,3(Siaα2,3Galβ1,4GlcNAcβ1,6)Gal.

### Claim 3 (depends on 1)

The immunity inducer according to claim 1, wherein the target oligosaccharide antigen R is an oligosaccharide antigen included in a mammal-derived glycoprotein O-linked sugar chain selected from the group consisting of Siaα2,3Galβ1,3GalNAc, Galβ1,3GalNAc, Siaα2,3Galβ1,3(GlcNAcβ1,6)GalNAc, GalNAcα1,3GalNAc, GlcNAcβ1,3(Siaα2,6)GalNAc, GalNAcα1,6GalNAc, GlcNAcβ1,6GalNAc, Fucα1,2GalNAc, Galβ1,3(GlcNAcβ1,6)GalNAc, Siaα2,6GalNAc, Siaα2,6(GlcNAcβ1,6)GalNAc, Siaα2,3Galβ1,3(Siaα2,6)GalNAc, Galβ1,4GalNAc, Siaα2,3Galβ1,4GalNAc, GlcNAcα1,4Gal, GlcNAcα1,4Galβ1,4GlcNAc, GlcNAcα1,4Galβ1,4GalNAc, GlcNAcα1,4Galβ1,4(GlcNAcα1,4Galβ1,4GlcNAcβ1,6)GalNAc, Siaα2,3Galβ1,4(Fucα1,3)GlcNAc(6SO4)β1,6GalNAc, Gal(3SO4)β1,4GlcNAcβ1,6(Siaα2,3Galβ1,3)GalNAc, Siaα2,3Galβ1,4(Fucα1,3)GlcNAc(6SO4)β1,3Galβ1,3GalNAc, Siaα2,3Galβ1,4(Fucα1,3)GlcNAc(6SO4)β1,3Galβ1,3(Siaα2,3Galβ1,4(Fucα1,3)GlcNAc(6SO4)β1,6)GalNAc, Siaα2,3Gal(6SO4) β1,4GlcNAcβ1,3Galβ1,3GalNAc, Gal(3SO4)β1,3GalNAc(6SO4), Siaα2,3Galβ1,3GalNAc(6SO4), Gal(3SO4)β1,3(Siaα2,6)GalNAc, and Gal(3SO4)β1,3GalNAc.

### Claim 4 (depends on 1)

The immunity inducer according to claim 1, wherein the target oligosaccharide antigen R is an oligosaccharide antigen included in a mammal-derived glycosaminoglycan type sugar chain selected from the group consisting of Galβ1,4Xyl, Galβ1,3Galβ1,4Xyl, GlcAβ1,3Galβ1,3Galβ1,4Xyl, GalNAcβ1,4IdoAα1,3Galβ1,3Galβ1,4Xyl, GalNAcβ1,4GlcAβ1,3Galβ1,3Galβ1,4Xyl, GlcNAcα1,4GlcAβ1,3Galβ1,3Galβ1,4Xyl, GlcAβ1,3GalNAcβ1,4GlcA, GalNAcβ1,4GlcAβ1,3GalNAc, GlcAβ1,3GalNAc(4SO4)β1,4GlcA, GalNAc(4SO4)β1,4GlcAβ1,3GalNAc, GlcAβ1,3GalNAc(6SO4)β1,4GlcA, GalNAc(6SO4)β1,4GlcAβ1,3GalNAc, GlcA(2SO4)β1,3(6SO4)GalNAcβ1,4GlcA, GalNAc(6SO4)β1,4GlcA(2SO4)β1,3GalNAc, GlcAβ1,3GalNAc(4,6SO4)β1,4GlcA, GalNAc(4,6SO4)β1,4GlcAβ1,3GalNAc, GalNAc(4,6SO4)β1,4GlcA(2SO4)β1,3GalNAc(6SO4), IdoAα1,3GalNAcβ1,4IdoA, GalNAcβ1,4IdoAα1,3GalNAc, IdoAα1,3GalNAc(4SO4)β1,4IdoA, GalNAc(4SO4)β1,4IdoAα1,3GalNAc, GlcAβ1,4GlcNAcα1,4GlcA, GlcNAcα1,4GlcAβ1,4GlcNAc, GlcA(2SO4)β1,4GlcNAcα1,4GlcA, GlcNAcα1,4GlcA(2SO4)β1,4GlcNAc, IdoA(2SO4)α1,4GlcNAcα1,4GlcA, GlcNAcα1,4IdoA(2SO4)α1,4GlcNAc, GlcA(2SO4)β1,4GlcNSO3α1,4GlcA, GlcNSO3α1,4GlcA(2SO4)β1,4GlcNAc, IdoA(2SO4)α1,4GlcNSO3Hα1,4GlcA, GlcNSO3α1,4IdoA(2SO4)α1,4GlcNAc, GlcAβ1,4GlcNα1,4GlcA, GlcAβ1,4GlcNSO3α1,4GlcA, GlcNSO3α1,4GlcAβ1,4GlcNAc, IdoAα1,4GlcNSO3α1,4GlcA, GlcNSO3α1,4IdoAα1,4GlcNAc, GlcAβ1,4GlcNSO3(6SO4)α1,4GlcA, GlcNSO3(6SO4)α1,4GlcAβ1,4GlcNAc, IdoAα1,4GlcNSO3(6SO4)α1,4GlcA, GlcNSO3(6SO4)α1,4IdoAα1,4GlcNAc, IdoA(2SO4)α1,4GlcNSO3(6SO4)α1,4GlcA, GlcNSO3(6SO4)α1,4IdoA(2SO4)α1,4GlcNAc, IdoAα1,4GlcNSO3α1,4IdoA, GlcAβ1,3GlcNAcβ1,4GlcA, GlcNAcβ1,4GlcAβ1,3GlcNAc, IdoAα1,4GlcNSO3, IdoAα1,4GlcNSO3(6SO4), IdoA(2SO4)α1,4GlcNSO3, IdoA(2SO4)α1,4GlcNSO3(6SO4), IdoA(2SO4)α1,4GlcNSO3(3SO4), GlcAβ1,4GlcNSO3, GlcAβ1,4GlcNSO3(6SO4), GlcA(2SO4)β1,4GlcNAc, GlcA(2SO4)β1,4GlcNSO3(3SO4), GlcAβ1,4GlcNSO3(3,6SO4), and GlcAβ1,4GlcNSO3(3SO4).

### Claim 5

An artificial glycolipid having chemical formula (2) or a salt thereof:
R—Z—Y—CH(NH—CO—(CH2)n1—CH3)—(CH2)n2—CH3 chemical formula (2)
wherein, in the chemical formula (2), R represents a linear chain or branched oligosaccharide constituted with 2 to 30 of one type or plural types of monosaccharides, Z represents a single bond, O, S or NH, a linker bound to thiomethyl, or an aminomethylated sugar alcohol, Y represents —(CH2)m—, n1 represents an integer from 20 to 40, n2 represents an integer from 1 to 27, and m represents an integer from 1 to 30, and
wherein R is an oligosaccharide antigen selected from the group consisting of
an oligosaccharide antigen included in a mammal-derived glycoprotein N-linked sugar chain selected from the group consisting of Siaα2,6Galβ1,4GlcNAc, Siaα2,3Galβ1,4GlcNAc, Galβ1,4GlcNAc, Galβ1,3GlcNAc, Siaα2,3Galβ1,4(Fucα1,3)GlcNAc, Galβ1,4 (Fucα1,3)GlcNAc, Siaα2,3Galβ1,3(Fucα1,4)GlcNAc, Siaα2,3Galβ1,3GlcNAc, Galβ1,3(Fucα1,4)GlcNAc, Siaα2,3Galβ1,3 (Siaα2,6)GlcNAc, Siaα2,3Galβ1,3 (Fucα1,4)(Siaα2,6)GlcNAc, Fucα1,2Galβ1,3(Fucα1,4)GlcNAc, Fucα1,2Galβ1,4GlcNAc, Fucα1,2Galβ1,4(Fucα1,3)GlcNAc, Fucα1,6GlcNAc, GlcNAcβ1,4 (Fucα1,6)GlcNAc, Manβ1,4GlcNAcβ1,4(Fucα1,6)GlcNAc, Manα1,6(Manα1,3)Manβ1,4GlcNAcβ1,4(Fucα1,6)GlcNAc, Manα1,6 (GlcNAcβ1,4) (Manα1,3)Manβ1,4GlcNAcβ1,4GlcNAc, Manα1,6 (GlcNAcβ1,4) (Manα1,3)Manβ1,4GlcNAcβ1,4(Fucα1,6)GlcNAc, GlcNAcβ1,4GlcNAc, Manβ1,4GlcNAcβ1,4 GlcNAc, GlcNAcβ1,2Man, GlcNAcβ1,4Man, GlcNAcβ1,6Man, Galβ1,3GlcNAcβ1,2Man, Galβ1,3GlcNAcβ1,4Man, Galβ1,3GlcNAcβ1,6Man, Galβ1,4GlcNAcβ1,2Man, Galβ1,4GlcNAcβ1,4Man, Galβ1,4GlcNAcβ1,6Man, Siaα2,3Galβ1,4GlcNAcβ1,2Man, Siaα2,3Galβ1,4GlcNAcβ1,4Man, Siaα2,3Galβ1,4GlcNAcβ1,6Man, Siaα2,3Galβ1,3GlcNAcβ1,2Man, Siaα2,3Galβ1,3GlcNAcβ1,4Man, Siaα2,3Galβ1,3GlcNAcβ1,6Man, Siaα2,6Galβ1,4GlcNAcβ1,2Man, Siaα2,6Galβ1,4GlcNAcβ1,4Man, Siaα2,6Galβ1,4GlcNAcβ1,6Man, GalNAcβ1,4GlcNAc, GalNAcβ1,4GlcNAcβ1,2Man, GalNAc(4SO4)β1,4GlcNAc, GalNAc(4SO4)β1,4GlcNAcβ1,2Man, GalNAc(4SO4)β1,4GlcNAcβ1,4Man, GalNAc(4SO4)β1,4GlcNAcβ1,6Man, GlcAβ1,3Galβ1,4GlcNAc, GlcA(3SO4)β1,3Galβ1,4GlcNAc, Siaα2,3Galβ1,4(Fucα1,3)GlcNAc(6SO4), Siaα2,3Galβ1,4GlcNAc(6SO4), Galβ1,4GlcNAc(6SO4), Galβ1,4(Fucα1,3) GlcNAc(6SO4), Siaα2,3Gal(6SO4)β1,4(Fucα1,3)GlcNAc, Siaα2,3Gal(6SO4)β1,4GlcNAc, Gal(6SO4)β1,4GlcNAc, Gal(6SO4)β1,4GlcNAc(6SO4), Galβ1,4GlcNAcβ1,3Gal, GlcNAcβ1,3Galβ1,4GlcNAc, Galβ1,4GlcNAc(6SO4)β1,3Gal, GlcNAc(6SO4)β1,3Galβ1,4GlcNAc, Gal(6SO4)β1,4GlcNAc(6SO4)β1,3Gal, GlcNAc(6SO4)β1,3Gal(6SO4)β1,4GlcNAc, Siaα2,3Galβ1,4GlcNAcβ1,3Galβ1,4(Fucα1,3)GlcNAc, Fucα1,2Galβ1,3GlcNAc, Galα1,3(Fucα1,2)Galβ1,3GlcNAc, Galα1,3(Fucα1,2)Galβ1,4GlcNAc, GalNAcα1,3(Fucα1,2)Galβ1,3GlcNAc, GalNAcα1,3(Fucα1,2)Galβ1,4GlcNAc, Fucα1,2Galβ1,4(Fucα1,3)GlcNAcβ1,3Gal, Gal(3SO4)β1,4GlcNAc, Gal(3SO4)β1,4(Fucα1,3)GlcNAc, Gal(3SO4)β1,3GlcNAc, Gal(3SO4)β1,3(Fucα1,4)GlcNAc, Gal(3SO4)β1,4GlcNAc(6SO4), Gal(3SO4)β1,4(Fucα1,3)GlcNAc(6SO4), Siaα2,8Siaα2,8Sia, Siaα2,6GalNAcβ1,4GlcNAc, Siaα2,3Galβ1,4(Fucα1,3)GlcNAcβ1,3Galβ1,4(Fucα1,3)GlcNAc, Galβ1,4GlcNAcβ1,3(Galβ1,4GlcNAcβ1,6)Gal, and Siaα2,3Galβ1,4GlcNAcβ1,3(Siaα2,3Galβ1,4GlcNAcβ1,6)Gal,
an oligosaccharide antigen included in a mammal-derived glycoprotein O-linked sugar chain selected from the group consisting of Siaα2,3Galβ1,3GalNAc, Galβ1,3GalNAc, Siaα2,3Galβ1,3(GlcNAcβ1,6)GalNAc, GalNAcα1,3GalNAc, GlcNAcβ1,3(Siaα2,6)GalNAc, GalNAcα1,6GalNAc, GlcNAcβ1,6GalNAc, Fucα1,2GalNAc, Galβ1,3(GlcNAcβ1,6)GalNAc, Siaα2,6GalNAc, Siaα2,6(GlcNAcβ1,6)GalNAc, Siaα2,3Galβ1,3(Siaα2,6)GalNAc, Galβ1,4GalNAc, Siaα2,3Galβ1,4GalNAc, GlcNAcα1,4Gal, GlcNAcα1,4Galβ1,4GlcNAc, GlcNAcα1,4Galβ1,4GalNAc, GlcNAcα1,4Galβ1,4(GlcNAcα1,4Galβ1,4GlcNAcβ1,6)GalNAc, Siaα2,3Galβ1,4(Fucα1,3)GlcNAc(6SO4)β1,6GalNAc, Gal(3SO4)β1,4GlcNAcβ1,6(Siaα2,3Galβ1,3)GalNAc, Siaα2,3Galβ1,4(Fucα1,3)GlcNAc(6SO4)β1,3Galβ1,3GalNAc, Siaα2,3Galβ1,4(Fucα1,3)GlcNAc(6SO4)β1,3Galβ1,3(Siaα2,3Galβ1,4(Fucα1,3)GlcNAc(6SO4)β1,6)GalNAc, Siaα2,3Gal(6SO4) β1,4GlcNAcβ1,3Galβ1,3GalNAc, Gal(3SO4)β1,3GalNAc(6SO4), Siaα2,3Galβ1,3GalNAc(6SO4), Gal(3SO4)β1,3(Siaα2,6)GalNAc, and Gal(3SO4)β1,3GalNAc, and
an oligosaccharide antigen included in a mammal-derived glycosaminoglycan type sugar chain selected from the group consisting of Galβ1,4Xyl, Galβ1,3Galβ1,4Xyl, GlcAβ1,3Galβ1,3Galβ1,4Xyl, GalNAcβ1,4IdoAα1,3Galβ1,3Galβ1,4Xyl, GalNAcβ1,4GlcAβ1,3Galβ1,3Galβ1,4Xyl, GlcNAcα1,4GlcAβ1,3Galβ1,3Galβ1,4Xyl, GlcAβ1,3GalNAcβ1,4GlcA, GalNAcβ1,4GlcAβ1,3GalNAc, GlcAβ1,3GalNAc(4SO4)β1,4GlcA, GalNAc(4SO4)β1,4 GlcAβ1,3GalNAc, GlcAβ1,3GalNAc(6SO4)β1,4GlcA, GalNAc(6SO4)β1,4 GlcAβ1,3GalNAc, GlcA(2SO4)β1,3(6SO4)GalNAcβ1,4GlcA, GalNAc(6SO4)β1,4GlcA(2SO4)β1,3GalNAc, GlcAβ1,3GalNAc(4,6SO4)β1,4GlcA, GalNAc(4,6SO4)β1,4GlcAβ1,3GalNAc, GalNAc(4,6SO4)β1,4GlcA(2SO4)β1,3GalNAc(6SO4), IdoAα1,3GalNAcβ1,4IdoA, GalNAcβ1,4IdoAα1,3GalNAc, IdoAα1,3GalNAc(4SO4)β1,4IdoA, GalNAc(4SO4)β1,4IdoAα1,3GalNAc, GlcAβ1,4GlcNAcα1,4GlcA, GlcNAcα1,4GlcAβ1,4GlcNAc, GlcA(2SO4)β1,4GlcNAcα1,4GlcA, GlcNAcα1,4GlcA(2SO4)β1,4GlcNAc, IdoA(2SO4)α1,4GlcNAcα1,4GlcA, GlcNAcα1,4IdoA(2SO4)α1,4GlcNAc, GlcA(2SO4)β1,4GlcNSO3α1,4GlcA, GlcNSO3α1,4GlcA(2SO4)β1,4GlcNAc, IdoA(2SO4)α1,4GlcNSO3Hα1,4GlcA, GlcNSO3α1,4IdoA(2SO4)α1,4GlcNAc, GlcAβ1,4GlcNα1,4GlcA, GlcAβ1,4GlcNSO3α1,4GlcA, GlcNSO3α1,4GlcAβ1,4GlcNAc, IdoAα1,4GlcNSO3α1,4GlcA, GlcNSO3α1,4IdoAα1,4GlcNAc, GlcAβ1,4GlcNSO3(6SO4)α1,4GlcA, GlcNSO3(6SO4)α1,4GlcAβ1,4GlcNAc, IdoAα1,4GlcNSO3(6SO4)α1,4GlcA, GlcNSO3(6SO4)α1,4IdoAα1,4GlcNAc, IdoA(2SO4)α1,4GlcNSO3(6SO4)α1,4GlcA, GlcNSO3(6SO4)α1,4IdoA(2SO4)α1,4GlcNAc, IdoAα1,4 GlcNSO3α1,4IdoA, GlcAβ1,3GlcNAcβ1,4GlcA, GlcNAcβ1,4GlcAβ1,3GlcNAc, IdoAα1,4GlcNSO3, IdoAα1,4GlcNSO3(6SO4), IdoA(2SO4)α1,4GlcNSO3, IdoA(2SO4)α1,4GlcNSO3(6SO4), IdoA(2SO4)α1,4GlcNSO3(3SO4), GlcAβ1,4GlcNSO3, GlcAβ1,4GlcNSO3(6SO4), GlcA(2SO4)β1,4GlcNAc, GlcA(2SO4)β1,4GlcNSO4(3SO4), GlcAβ1,4GlcNSO3(3,6SO4), and GlcAβ1,4GlcNSO3(3SO4).

### Claim 6 (depends on 5)

The glycolipid or the salt thereof according to claim 5, wherein R is an oligosaccharide antigen included in a mammal-derived glycoprotein N-linked sugar chain selected from the group consisting of Siaα2,6Galβ1,4GlcNAc, Siaα2,3Galβ1,4GlcNAc, Galβ1,4GlcNAc, Galβ1,3GlcNAc, Siaα2,3Galβ1,4(Fucα1,3)GlcNAc, Galβ1,4 (Fucα1,3)GlcNAc, Siaα2,3Galβ1,3(Fucα1,4)GlcNAc, Siaα2,3Galβ1,3GlcNAc, Galβ1,3(Fucα1,4)GlcNAc, Siaα2,3Galβ1,3 (Siaα2,6GlcNAc, Siaα2,3Galβ1,3 (Fucα1,4)(Siaα2,6)GlcNAc, Fucα1,2Galβ1,3(Fucα1,4)GlcNAc, Fucα1,2Galβ1,4GlcNAc, Fucα1,2Galβ1,4(Fucα1,3)GlcNAc, Fucα1,6GlcNAc, GlcNAcβ1,4 (Fucα1,6)GlcNAc, Manβ1,4GlcNAcβ1,4(Fucα1,6)GlcNAc, Manα1,6(Manα1,3)Manβ1,4GlcNAcβ1,4(Fucα1,6)GlcNAc, Manα1,6 (GlcNAcβ1,4) (Manα1,3)Manβ1,4GlcNAcβ1,4GlcNAc, Manα1,6 (GlcNAcβ1,4) (Manα1,3)Manβ1,4GlcNAcβ1,4(Fucα1,6)GlcNAc, GlcNAcβ1,4GlcNAc, Manβ1,4GlcNAcβ1,4GlcNAc, GlcNAcβ1,2Man, GlcNAcβ1,4Man, GlcNAcβ1,6Man, Galβ1,3GlcNAcβ1,2Man, Galβ1,3GlcNAcβ1,4Man, Galβ1,3GlcNAcβ1,6Man, Galβ1,4GlcNAcβ1,2Man, Galβ1,4GlcNAcβ1,4Man, Galβ1,4GlcNAcβ1,6Man, Siaα2,3Galβ1,4GlcNAcβ1,2Man, Siaα2,3Galβ1,4GlcNAcβ1,4Man, Siaα2,3Galβ1,4GlcNAcβ1,6Man, Siaα2,3Galβ1,3GlcNAcβ1,2Man, Siaα2,3Galβ1,3GlcNAcβ1,4Man, Siaα2,3Galβ1,3GlcNAcβ1,6Man, Siaα2,6Galβ1,4GlcNAcβ1,2Man, Siaα2,6Galβ1,4GlcNAcβ1,4Man, Siaα2,6Galβ1,4GlcNAcβ1,6Man, GalNAcβ1,4GlcNAc, GalNAcβ1,4GlcNAcβ1,2Man, GalNAc(4SO4)β1,4GlcNAc, GalNAc(4SO4)β1,4GlcNAcβ1,2Man, GalNAc(4SO4)β1,4GlcNAcβ1,4Man, GalNAc(4SO4)β1,4GlcNAcβ1,6Man, GlcAβ1,3Galβ1,4GlcNAc, GlcA(3SO4)β1,3Galβ1,4GlcNAc, Siaα2,3Galβ1,4(Fucα1,3)GlcNAc(6SO4), Siaα2,3Galβ1,4GlcNAc(6SO4), Galβ1,4GlcNAc(6SO4), Galβ1,4(Fucα1,3) GlcNAc(6SO4), Siaα2,3Gal(6SO4)β1,4(Fucα1,3)GlcNAc, Siaα2,3Gal(6SO4)β1,4GlcNAc, Gal(6SO4)β1,4GlcNAc, Gal(6SO4)β1,4GlcNAc(6SO4), Galβ1,4GlcNAcβ1,3Gal, GlcNAcβ1,3Galβ1,4GlcNAc, Galβ1,4GlcNAc(6SO4)β1,3Gal, GlcNAc(6SO4)β1,3Galβ1,4GlcNAc, Gal(6SO4)β1,4GlcNAc(6SO4)β1,3Gal, GlcNAc(6SO4)β1,3Gal(6SO4)β1,4GlcNAc, Siaα2,3Galβ1,4GlcNAcβ1,3Galβ1,4(Fucα1,3)GlcNAc, Fucα1,2Galβ1,3GlcNAc, Galα1,3(Fucα1,2)Galβ1,3GlcNAc, Galα1,3(Fucα1,2)Galβ1,4GlcNAc, GalNAcα1,3(Fucα1,2)Galβ1,3GlcNAc, GalNAcα1,3(Fucα1,2)Galβ1,4GlcNAc, Fucα1,2Galβ1,4(Fucα1,3)GlcNAcβ1,3Gal, Gal(3SO4)β1,4GlcNAc, Gal(3SO4)β1,4(Fucα1,3)GlcNAc, Gal(3SO4)β1,3GlcNAc, Gal(3SO4)β1,3(Fucα1,4)GlcNAc, Gal(3SO4)β1,4GlcNAc(6SO4), Gal(3SO4)β1,4(Fucα1,3)GlcNAc(6SO4), Siaα2,8Siaα2,8Sia, Siaα2,6GalNAcβ1,4GlcNAc, Siaα2,3Galβ1,4(Fucα1,3)GlcNAcβ1,3Galβ1,4(Fucα1,3)GlcNAc, Galβ1,4GlcNAcβ1,3(Galβ1,4GlcNAcβ1,6)Gal, and Siaα2,3Galβ1,4GlcNAcβ1,3(Siaα2,3Galβ1,4GlcNAcβ1,6)Gal.

### Claim 7 (depends on 5)

The glycolipid or the salt thereof according to claim 5, wherein R is an oligosaccharide antigen included in a mammal-derived glycoprotein O-linked sugar chain selected from the group consisting of Siaα2,3Galβ1,3GalNAc, Galβ1,3GalNAc, Siaα2,3Galβ1,3(GlcNAcβ1,6)GalNAc, GalNAcα1,3GalNAc, GlcNAcβ1,3(Siaα2,6)GalNAc, GalNAcα1,6GalNAc, GlcNAcβ1,6GalNAc, Fucα1,2GalNAc, Galβ1,3(GlcNAcβ1,6)GalNAc, Siaα2,6GalNAc, Siaα2,6(GlcNAcβ1,6)GalNAc, Siaα2,3Galβ1,3(Siaα2,6)GalNAc, Galβ1,4GalNAc, Siaα2,3Galβ1,4GalNAc, GlcNAcα1,4Gal, GlcNAcα1,4Galβ1,4GlcNAc, GlcNAcα1,4Galβ1,4GalNAc, GlcNAcα1,4Galβ1,4(GlcNAcα1,4Galβ1,4GlcNAcβ1,6)GalNAc, Siaα2,3Galβ1,4(Fucα1,3)GlcNAc(6SO4)β1,6GalNAc, GalβSO4)β1,4GlcNAcβ1,6(Siaα2,3Galβ1,3)GalNAc, Siaα2,3Galβ1,4(Fucα1,3)GlcNAc(6SO4)β1,3Galβ1,3GalNAc, Siaα2,3Galβ1,4(Fucα1,3)GlcNAc(6SO4)β1,3Galβ1,3(Siaα2,3Galβ1,4(Fucα1,3)GlcNAc(6SO4)β1,6)GalNAc, Siaα2,3Gal(6SO4) β1,4GlcNAcβ1,3Galβ1,3GalNAc, Gal(3SO4)β1,3GalNAc(6SO4), Siaα2,3Galβ1,3GalNAc(6SO4), Gal(3SO4)β1,3(Siaα2,6)GalNAc, and Gal(3SO4)β1,3GalNAc.

### Claim 8 (depends on 5)

The glycolipid or the salt thereof according to claim 5, wherein R is an oligosaccharide antigen included in a mammal-derived glycosaminoglycan type sugar chain selected from the group consisting of Galβ1,4Xyl, Galβ1,3Galβ1,4Xyl, GlcAβ1,3Galβ1,3Galβ1,4Xyl, GalNAcβ1,4IdoAα1,3Galβ1,3Galβ1,4Xyl, GalNAcβ1,4GlcAβ1,3Galβ1,3Galβ1,4Xyl, GlcNAcα1,4GlcAβ1,3Galβ1,3Galβ1,4Xyl, GlcAβ1,3GalNAcβ1,4GlcA, GalNAcβ1,4GlcAβ1,3GalNAc, GlcAβ1,3GalNAc(4SO4)β1,4GlcA, GalNAc(4SO4)β1,4 GlcAβ1,3GalNAc, GlcAβ1,3GalNAc(6SO4)β1,4GlcA, GalNAc(6SO4)β1,4GlcAβ1,3GalNAc, GlcA(2SO4)β1,3(6SO4)GalNAcβ1,4GlcA, GalNAc(6SO4)β1,4GlcA(2SO4)β1,3GalNAc, GlcAβ1,3GalNAc(4,6SO4)β1,4GlcA, GalNAc(4,6SO4)β1,4GlcAβ1,3GalNAc, GalNAc(4,6SO4)β1,4GlcA(2SO4)β1,3GalNAc(6SO4), IdoAα1,3GalNAcβ1,4IdoA, GalNAcβ1,4IdoAα1,3GalNAc, IdoAα1,3GalNAc(4SO4)β1,4IdoA, GalNAc(4SO4)β1,4IdoAα1,3GalNAc, GlcAβ1,4GlcNAcα1,4GlcA, GlcNAcα1,4GlcAβ1,4GlcNAc, GlcA(2SO4)β1,4GlcNAcα1,4GlcA, GlcNAcα1,4GlcA(2SO4)β1,4GlcNAc, IdoA(2SO4)α1,4GlcNAcα1,4GlcA, GlcNAcα1,4IdoA(2SO4)α1,4GlcNAc, GlcA(2SO4)β1,4GlcNSO3α1,4GlcA, GlcNSO3α1,4GlcA(2SO4)β1,4GlcNAc, IdoA(2SO4)α1,4GlcNSO3Hα1,4GlcA, GlcNSO3α1,4IdoA(2SO4)α1,4GlcNAc, GlcAβ1,4GlcNα1,4GlcA, GlcAβ1,4GlcNSO3α1,4GlcA, GlcNSO3α1,4GlcAβ1,4GlcNAc, IdoAα1,4GlcNSO3α1,4GlcA, GlcNSO3α1,4IdoAα1,4GlcNAc, GlcAβ1,4GlcNSO3(6SO4)α1,4GlcA, GlcNSO3(6SO4)α1,4GlcAβ1,4GlcNAc, IdoAα1,4GlcNSO3(6SO4)α1,4GlcA, GlcNSO3(6SO4)α1,4IdoAα1,4GlcNAc, IdoA(2SO4)α1,4GlcNSO3(6SO4)α1,4GlcA, GlcNSO3(6SO4)α1,4IdoA(2SO4)α1,4GlcNAc, IdoAα1,4 GlcNSO3α1,4IdoA, GlcAβ1,3GlcNAcβ1,4GlcA, GlcNAcβ1,4GlcAβ1,3GlcNAc, IdoAα1,4GlcNSO3, IdoAα1,4GlcNSO3(6SO4), IdoA(2SO4)α1,4GlcNSO3, IdoA(2SO4)α1,4GlcNSO3(6SO4), IdoA(2SO4)α1,4GlcNSO3(3SO4), GlcAβ1,4GlcNSO3, GlcAβ1,4GlcNSO3(6SO4), GlcA(2SO4)β1,4GlcNAc, GlcA(2SO4)β1,4GlcNSO3(3SO4), GlcAβ1,4GlcNSO3(3,6SO4), and GlcAβ1,4GlcNSO3(3SO4).

### Claim 9

A vaccine comprising an artificial glycolipid or a salt thereof as an effective component, wherein the artificial glycolipid has the chemical formula (2) and includes the target oligosaccharide antigen R:
R—Z—Y—CH(NH—CO—(CH2)n1—CH3)—(CH2)n2—CH3 chemical formula (2)
wherein, in the chemical formula (2), R represents a linear chain or branched oligosaccharide constituted with 2 to 30 of one type or plural types of monosaccharides, Z represents a single bond, O, S or NH, a linker bound to thiomethyl, or an aminomethylated sugar alcohol, Y represents —(CH2)m—, n1 represents an integer from 2 to 40, n2 represents an integer from 1 to 27, and m represents an integer from 1 to 30, and
wherein the target oligosaccharide antigen R is selected from the group consisting of an oligosaccharide antigen included in a mammal-derived glycoprotein N-linked sugar chain, an oligosaccharide antigen included in a mammal-derived glycoprotein O-linked sugar chain, and an oligosaccharide antigen included in a mammal-derived glycosaminoglycan type sugar chain.

### Claim 10 (depends on 9)

The vaccine according to claim 9, wherein the target oligosaccharide antigen R is an oligosaccharide antigen included in a mammal-derived glycoprotein N-linked sugar chain selected from the group consisting of Siaα2,6Galβ1,4GlcNAc, Siaα2,3Galβ1,4GlcNAc, Galβ1,4GlcNAc, Galβ1,3GlcNAc, Siaα2,3Galβ1,4(Fucα1,3)GlcNAc, Galβ1,4 (Fucα1,3)GlcNAc, Siaα2,3Galβ1,3(Fucα1,4)GlcNAc, Siaα2,3Galβ1,3GlcNAc, Galβ1,3(Fucα1,4)GlcNAc, Siaα2,3Galβ1,3 (Siaα2,6)GlcNAc, Siaα2,3Galβ1,3(Fucα1,4)(Siaα2,6)GlcNAc, Fucα1,2Galβ1,3(Fucα1,4)GlcNAc, Fucα1,2Galβ1,4GlcNAc, Fucα1,2Galβ1,4(Fucα1,3)GlcNAc, Fucα1,6GlcNAc, GlcNAcβ1,4 (Fucα1,6)GlcNAc, Manβ1,4GlcNAcβ1,4(Fucα1,6)GlcNAc, Manα1,6(Manα1,3)Manβ1,4GlcNAcβ1,4(Fucα1,6)GlcNAc, Manα1,6 (GlcNAcβ1,4) (Manα1,3)Manβ1,4GlcNAcβ1,4GlcNAc, Manα1,6(GlcNAcβ1,4) (Manα1,3)Manβ1,4GlcNAcβ1,4(Fucα1,6)GlcNAc, GlcNAcβ1,4GlcNAc, Manβ1,4GlcNAcβ1,4GlcNAc, GlcNAcβ1,2Man, GlcNAcβ1,4Man, GlcNAcβ1,6Man, Galβ1,3GlcNAcβ1,2Man, Galβ1,3GlcNAcβ1,4Man, Galβ1,3GlcNAcβ1,6Man, Galβ1,4GlcNAcβ1,2Man, Galβ1,4GlcNAcβ1,4Man, Galβ1,4GlcNAcβ1,6Man, Siaα2,3Galβ1,4GlcNAcβ1,2Man, Siaα2,3Galβ1,4GlcNAcβ1,4Man, Siaα2,3Galβ1,4GlcNAcβ1,6Man, Siaα2,3Galβ1,3GlcNAcβ1,2Man, Siaα2,3Galβ1,3GlcNAcβ1,4Man, Siaα2,3Galβ1,3GlcNAcβ1,6Man, Siaα2,6Galβ1,4GlcNAcβ1,2Man, Siaα2,6Galβ1,4GlcNAcβ1,4Man, Siaα2,6Galβ1,4GlcNAcβ1,6Man, GalNAcβ1,4GlcNAc, GalNAcβ1,4GlcNAcβ1,2Man, GalNAc(4SO4)β1,4GlcNAc, GalNAc(4SO4)β1,4GlcNAcβ1,2Man, GalNAc(4SO4)β1,4GlcNAcβ1,4Man, GalNAc(4SO4)β1,4GlcNAcβ1,6Man, GlcAβ1,3Galβ1,4GlcNAc, GlcA(3SO4)β1,3Galβ1,4GlcNAc, Siaα2,3Galβ1,4 (Fucα1,3)GlcNAc(6SO4), Siaα2,3Galβ1,4GlcNAc(6SO4), Galβ1,4 GlcNAc(6SO4), Galβ1,4(Fucα1,3) GlcNAc(6SO4), Siaα2,3Gal(6SO4)β1,4 (Fucα1,3)GlcNAc, Siaα2,3Gal(6SO4)β1,4GlcNAc, Gal(6SO4)β1,4GlcNAc, Gal(6SO4)β1,4GlcNAc(6SO4), Galβ1,4GlcNAcβ1,3Gal, GlcNAcβ1,3Galβ1,4GlcNAc, Galβ1,4GlcNAc(6SO4)β1,3Gal, GlcNAc(6SO4)β1,3Galβ1,4GlcNAc, Gal(6SO4)β1,4GlcNAc(6SO4)β1,3Gal, GlcNAc(6SO4)β1,3Gal(6SO4)β1,4GlcNAc, Siaα2,3Galβ1,4GlcNAcβ1,3Galβ1,4(Fucα1,3)GlcNAc, Fucα1,2Galβ1,3GlcNAc, Galα1,3(Fucα1,2)Galβ1,3GlcNAc, Galα1,3(Fucα1,2)Galβ1,4GlcNAc, GalNAcα1,3(Fucα1,2)Galβ1,3GlcNAc, GalNAcα1,3(Fucα1,2)Galβ1,4GlcNAc, Fucα1,2Galβ1,4(Fucα1,3)GlcNAcβ1,3Gal, Gal(3SO4)β1,4GlcNAc, Gal(3SO4)β1,4(Fucα1,3)GlcNAc, Gal(3SO4)β1,3GlcNAc, Gal(3SO4)β1,3(Fucα1,4)GlcNAc, Gal(3SO4)β1,4GlcNAc(6SO4), Gal(3SO4)β1,4(Fucα1,3)GlcNAc(6SO4), Siaα2,8Siaα2,8Sia, Siaα2,6GalNAcβ1,4GlcNAc, Siaα2,3Galβ1,4(Fucα1,3)GlcNAcβ1,3Galβ1,4(Fucα1,3)GlcNAc, Galβ1,4GlcNAcβ1,3(Galβ1,4GlcNAcβ1,6)Gal, and Siaα2,3Galβ1,4GlcNAcβ1,3(Siaα2,3Galβ1,4GlcNAcβ1,6)Gal.

### Claim 11 (depends on 9)

The vaccine according to claim 9, wherein the target oligosaccharide antigen R is an oligosaccharide antigen included in a mammal-derived glycoprotein O-linked sugar chain selected from the group consisting of Siaα2,3Galβ1,3GalNAc, Galβ1,3GalNAc, Siaα2,3Galβ1,3(GlcNAcβ1,6)GalNAc, GalNAcα1,3GalNAc, GlcNAcβ1,3(Siaα2,6)GalNAc, GalNAcα1,6GalNAc, GlcNAcβ1,6GalNAc, Fucα1,2GalNAc, Galβ1,3(GlcNAcβ1,6)GalNAc, Siaα2,6GalNAc, Siaα2,6(GlcNAcβ1,6)GalNAc, Siaα2,3Galβ1,3(Siaα2,6)GalNAc, Galβ1,4GalNAc, Siaα2,3Galβ1,4GalNAc, GlcNAcα1,4Gal, GlcNAcα1,4Galβ1,4GlcNAc, GlcNAcα1,4Galβ1,4GalNAc, GlcNAcα1,4Galβ1,4(GlcNAcα1,4Galβ1,4GlcNAcβ1,6)GalNAc, Siaα2,3Galβ1,4(Fucα1,3)GlcNAc(6SO4)β1,6GalNAc, GalβSO4)β1,4GlcNAcβ1,6(Siaα2,3Galβ1,3)GalNAc, Siaα2,3Galβ1,4(Fucα1,3)GlcNAc(6SO4)β1,3Galβ1,3GalNAc, Siaα2,3Galβ1,4(Fucα1,3)GlcNAc(6SO4)β1,3Galβ1,3(Siaα2,3Galβ1,4(Fucα1,3)GlcNAc(6SO4)β1 ,6)GalNAc, Siaα2,3Gal(6SO4)β1,4GlcNAcβ1,3Galβ1,3GalNAc, Gal(3SO4)β1,3GalNAc(6SO4), Siaα2,3Galβ1,3GalNAc(6SO4), Gal(3SO4)β1,3(Siaα2,6)GalNAc, and Gal(3SO4)β1,3GalNAc.

### Claim 12 (depends on 9)

The vaccine according to claim 9, wherein the target oligosaccharide antigen R is an oligosaccharide antigen included in a mammal-derived glycosaminoglycan type sugar chain selected from the group consisting of Galβ1,4Xyl, Galβ1,3Galβ1,4Xyl, GlcAβ1,3Galβ1,3Galβ1,4Xyl, GalNAcβ1,4IdoAα1,3Galβ1,3Galβ1,4Xyl, GalNAcβ1,4GlcAβ1,3Galβ1,3Galβ1,4Xyl, GlcNAcα1,4GlcAβ1,3Galβ1,3Galβ1,4Xyl, GlcAβ1,3GalNAcβ1,4GlcA, GalNAcβ1,4GlcAβ1,3GalNAc, GlcAβ1,3GalNAc(4SO4)β1,4GlcA, GalNAc(4SO4)β1,4GlcAβ1,3GalNAc, GlcAβ1,3GalNAc(6SO4)β1,4GlcA, GalNAc(6SO4)β1,4GlcAβ1,3GalNAc, GlcA(2SO4)β1,3(6SO4)GalNAcβ1,4GlcA, GalNAc(6SO4)β1,4GlcA(2SO4)β1,3GalNAc, GlcAβ1,3GalNAc(4,6SO4)β1,4GlcA, GalNAc(4,6SO4)β1,4GlcAβ1,3GalNAc, GalNAc(4,6SO4)β1,4GlcA(2SO4)β1,3GalNAc(6SO4), IdoAα1,3GalNAcβ1,4IdoA, GalNAcβ1,4IdoAα1,3GalNAc, IdoAα1,3GalNAc(4SO4)β1,4IdoA, GalNAc(4SO4)β1,4IdoAα1,3GalNAc, GlcAβ1,4GlcNAcα1,4GlcA, GlcNAcα1,4GlcAβ1,4GlcNAc, GlcA(2SO4)β1,4GlcNAcα1,4GlcA, GlcNAcα1,4GlcA(2SO4)β1,4GlcNAc, IdoA(2SO4)α1,4GlcNAcα1,4GlcA, GlcNAcα1,4IdoA(2SO4)β1,4GlcNAc, GlcA(2SO4)β1,4GlcNSO3α1,4GlcA, GlcNSO3α1,4GlcA(2SO4)β1,4GlcNAc, IdoA(2SO4)α1,4GlcNSO3Hα1,4GlcA, GlcNSO3α1,4IdoA(2SO4)α1,4GlcNAc, GlcAβ1,4GlcNα1,4GlcA, GlcAβ1,4GlcNSO3α1,4GlcA, GlcNSO3α1,4GlcAβ1,4GlcNAc, IdoAα1,4GlcNSO3α1,4GlcA, GlcNSO3α1,4IdoAα1,4GlcNAc, GlcAβ1,4GlcNSO3(6SO4)α1,4GlcA, GlcNSO3(6SO4)α1,4GlcAβ1,4GlcNAc, IdoAα1,4GlcNSO3(6SO4)α1,4GlcA, GlcNSO3(6SO4)α1,4IdoAα1,4GlcNAc, IdoA(2SO4)α1,4GlcNSO3(6SO4)α1,4GlcA, GlcNSO3(6SO4)α1,4IdoA(2SO4)α1,4GlcNAc, IdoAα1,4GlcNSO3α1,4IdoA, GlcAβ1,3GlcNAcβ1,4GlcA, GlcNAcβ1,4GlcAβ1,3GlcNAc, IdoAα1,4GlcNSO3, IdoAα1,4GlcNSO3(6SO4), IdoA(2SO4)α1,4GlcNSO3, IdoA(2SO4)α1,4GlcNSO3(6SO4), IdoA(2SO4)α1,4GlcNSO3(3SO4), GlcAβ1,4GlcNSO3, GlcAβ1,4GlcNSO3(6SO4), GlcA(2SO4)β1,4GlcNAc, GlcA(2SO4)β1,4GlcNSO3(3SO4), GlcAβ1,4GlcNSO3(3,6SO4), and GlcAβ1,4GlcNSO3(3SO4).

### Claim 13

An immunity inducing method antigen-specific to a target oligosaccharide antigen R in a mammal, comprising:
administering an immunity inducer comprising an artificial glycolipid or a salt thereof as an effective component to the mammal, wherein the artificial glycolipid has the chemical formula (2) and includes the target oligosaccharide antigen R:
R—Z—Y—CH(NH—CO—(CH2)n1—CH3)—(CH2)n2—CH3 chemical formula (2)
wherein, in the chemical formula (2), R represents a linear chain or branched oligosaccharide constituted with 2 to 30 of one type or plural types of monosaccharides, Z represents a single bond, O, S or NH, a linker bound to thiomethyl, or an aminomethylated sugar alcohol, Y represents —(CH2)m—, n1 represents an integer from 2 to 40, n2 represents an integer from 1 to 27, and m represents an integer from 1 to 30, and
wherein the target oligosaccharide antigen R is selected from the group consisting of an oligosaccharide antigen included in a mammal-derived glycoprotein N-linked sugar chain, an oligosaccharide antigen included in a mammal-derived glycoprotein O-linked sugar chain, and an oligosaccharide antigen included in a mammal-derived glycosaminoglycan type sugar chain.

### Claim 14 (depends on 13)

The immunity inducing method according to claim 13, wherein the target oligosaccharide antigen R is an oligosaccharide antigen included in a mammal-derived glycoprotein N-linked sugar chain selected from the group consisting of Siaα2,6Galβ1,4GlcNAc, Siaα2,3Galβ1,4GlcNAc, Galβ1,4GlcNAc, Galβ1,3GlcNAc, Siaα2,3Galβ1,4(Fucα1,3)GlcNAc, Galβ1,4 (Fucα1,3)GlcNAc, Siaα2,3Galβ1,3(Fucα1,4)GlcNAc, Siaα2,3Galβ1,3GlcNAc, Galβ1,3(Fucα1,4)GlcNAc, Siaα2,3Galβ1,3(Siaα2,6)GlcNAc, Siaα2,3Galβ1,3(Fucα1,4)(Siaα2,6)GlcNAc, Fucα1,2Galβ1,3(Fucα1,4)GlcNAc, Fucα1,2Galβ1,4GlcNAc, Fucα1,2Galβ1,4(Fucα1,3)GlcNAc, Fucα1,6GlcNAc, GlcNAcβ1,4 (Fucα1,6)GlcNAc, Manβ1,4GlcNAcβ1,4(Fucα1,6)GlcNAc, Manα1,6(Manα1,3)Manβ1,4GlcNAcβ1,4(Fucα1,6)GlcNAc, Manα1,6 (GlcNAcβ1,4) (Manα1,3)Manβ1,4GlcNAcβ1,4GlcNAc, Manα1,6(GlcNAcβ1,4) (Manα1,3)Manβ1,4GlcNAcβ1,4(Fucα1,6)GlcNAc, GlcNAcβ1,4GlcNAc, Manβ1,4GlcNAcβ1,4GlcNAc, GlcNAcβ1,2Man, GlcNAcβ1,4Man, GlcNAcβ1,6Man, Galβ1,3GlcNAcβ1,2Man, Galβ1,3GlcNAcβ1,4Man, Galβ1,3GlcNAcβ1,6Man, Galβ1,4GlcNAcβ1,2Man, Galβ1,4GlcNAcβ1,4Man, Galβ1,4GlcNAcβ1,6Man, Siaα2,3Galβ1,4GlcNAcβ1,2Man, Siaα2,3Galβ1,4GlcNAcβ1,4Man, Siaα2,3Galβ1,4GlcNAcβ1,6Man, Siaα2,3Galβ1,3GlcNAcβ1,2Man, Siaα2,3Galβ1,3GlcNAcβ1,4Man, Siaα2,3Galβ1,3GlcNAcβ1,6Man, Siaα2,6Galβ1,4GlcNAcβ1,2Man, Siaα2,6Galβ1,4GlcNAcβ1,4Man, Siaα2,6Galβ1,4GlcNAcβ1,6Man, GalNAcβ1,4GlcNAc, GalNAcβ1,4GlcNAcβ1,2Man, GalNAc(4SO4)β1,4GlcNAc, GalNAc(4SO4)β1,4GlcNAcβ1,2Man, GalNAc(4SO4)β1,4GlcNAcβ1,4Man, GalNAc(4SO4)β1,4GlcNAcβ1,6Man, GlcAβ1,3Galβ1,4GlcNAc, GlcA(3SO4)β1,3Galβ1,4GlcNAc, Siaα2,3Galβ1,4 (Fucα1,3)GlcNAc(6SO4), Siaα2,3Galβ1,4GlcNAc(6SO4), Galβ1,4GlcNAc(6SO4), Galβ1,4(Fucα1,3) GlcNAc(6SO4), Siaα2,3Gal(6SO4)β1,4 (Fucα1,3)GlcNAc, Siaα2,3Gal(6SO4)β1,4GlcNAc, Gal(6SO4)β1,4GlcNAc, Gal(6SO4)β1,4GlcNAc(6SO4), Galβ1,4GlcNAcβ1,3Gal, GlcNAcβ1,3Galβ1,4GlcNAc, Galβ1,4GlcNAc(6SO4)β1,3Gal, GlcNAc(6SO4)β1,3Galβ1,4GlcNAc, Gal(6SO4)β1,4GlcNAc(6SO4)β1,3Gal, GlcNAc(6SO4)β1,3Gal(6SO4)β1,4GlcNAc, Siaα2,3Galβ1,4GlcNAcβ1,3Galβ1,4(Fucα1,3)GlcNAc, Fucα1,2Galβ1,3GlcNAc, Galα1,3(Fucα1,2)Galβ1,3GlcNAc, Galα1,3(Fucα1,2)Galβ1,4GlcNAc, GalNAcα1,3(Fucα1,2)Galβ1,3GlcNAc, GalNAcα1,3(Fucα1,2)Galβ1,4GlcNAc, Fucα1,2Galβ1,4(Fucα1,3)GlcNAcβ1,3Gal, Gal(3SO4)β1,4GlcNAc, Gal(3SO4)β1,4(Fucα1,3)GlcNAc, Gal(3SO4)β1,3GlcNAc, Gal(3SO4)β1,3(Fucα1,4)GlcNAc, Gal(3SO4)β1,4GlcNAc(6SO4), Gal(3SO4)β1,4(Fucα1,3)GlcNAc(6SO4), Siaα2,8Siaα2,8Sia, Siaα2,6GalNAcβ1,4GlcNAc, Siaα2,3Galβ1,4(Fucα1,3)GlcNAcβ1,3Galβ1,4(Fucα1,3)GlcNAc, Galβ1,4GlcNAcβ1,3(Galβ1,4GlcNAcβ1,6)Gal, and Siaα2,3Galβ1,4GlcNAcβ1,3(Siaα2,3Galβ1,4GlcNAcβ1,6)Gal.

### Claim 15 (depends on 13)

The immunity inducing method according to claim 13, wherein the target oligosaccharide antigen R is an oligosaccharide antigen included in a mammal-derived glycoprotein O-linked sugar chain selected from the group consisting of Siaα2,3Galβ1,3GalNAc, Galβ1,3GalNAc, Siaα2,3Galβ1,3(GlcNAcβ1,6)GalNAc, GalNAcα1,3GalNAc, GlcNAcβ(Siaα2,6)GalNAc, GalNAcα1,6GalNAc, GlcNAcβ1,6GalNAc, Fucα1,2GalNAc, Galβ1,3(GlcNAcβ1,6)GalNAc, Siaα2,6GalNAc, Siaα2,6(GlcNAcβ1,6)GalNAc, Siaα2,3Galβ1,3(Siaα2,6)GalNAc, Galβ1,4GalNAc, Siaα2,3Galβ1,4GalNAc, GlcNAcα1,4Gal, GlcNAcα1,4Galβ1,4GlcNAc, GlcNAcα1,4Galβ1,4GalNAc, GlcNAcα1,4Galβ1,4(GlcNAcα1,4Galβ1,4GlcNAcβ1,6)GalNAc, Siaα2,3Galβ1,4(Fucα1,3)GlcNAc(6SO4)β1,6GalNAc, Galβ3SO4)β1,4GlcNAcβ1,6(Siaα2,3Galβ1,3)GalNAc, Siaα2,3Galβ1,4(Fucα1,3)GlcNAc(6SO4)β1,3Galβ1,3GalNAc, Siaα2,3Galβ1,4(Fucα1,3)GlcNAc(6SO4)β1,3Galβ1,3(Siaα2,3Galβ1,4(Fucα1,3)GlcNAc(6SO4)β1,6)GalNAc, Siaα2,3Gal(6SO4) β1,4GlcNAcβ1,3Galβ1,3GalNAc, Gal(3SO4)β1,3GalNAc(6SO4), Siaα2,3Galβ1,3GalNAc(6SO4), Gal(3SO4)β1,3(Siaα2,6)GalNAc, and Gal(3SO4)β1,3GalNAc.

### Claim 16 (depends on 13)

The immunity inducing method according to claim 13, wherein the target oligosaccharide antigen R is an oligosaccharide antigen included in a mammal-derived glycosaminoglycan type sugar chain selected from the group consisting of Galβ1,4Xyl, Galβ1,3Galβ1,4Xyl, GlcAβ1,3Galβ1,3Galβ1,4Xyl, GalNAcβ1,4IdoAα1,3Galβ1,3Galβ1,4Xyl, GalNAcβ1,4GlcAβ1,3Galβ1,3Galβ1,4Xyl, GlcNAcα1,4GlcAβ1,3Galβ1,3Galβ1,4Xyl, GlcAβ1,3GalNAcβ1,4GlcA, GalNAcβ1,4GlcAβ1,3GalNAc, GlcAβ1,3GalNAc(4SO4)β1,4GlcA, GalNAc(4SO4)β1,4 GlcAβ1,3GalNAc, GlcAβ1,3GalNAc(6SO4)β1,4GlcA, GalNAc(6SO4)β1,4GlcAβ1,3GalNAc, GlcA(2SO4)β1,3(6SO4)GalNAcβ1,4GlcA, GalNAc(6SO4)β1,4GlcA(2SO4)β1,3GalNAc, GlcAβ1,3GalNAc(4,6SO4)β1,4GlcA, GalNAc(4,6SO4)β1,4GlcAβ1,3GalNAc, GalNAc(4,6SO4)β1,4GlcA(2SO4)β1,3GalNAc(6SO4), IdoAα1,3GalNAcβ1,4IdoA, GalNAcβ1,4IdoAα1,3GalNAc, IdoAα1,3GalNAc(4SO4)β1,4IdoA, GalNAc(4SO4)β1,4IdoAα1,3GalNAc, GlcAβ1,4GlcNAcα1,4GlcA, GlcNAcα1,4GlcAβ1,4GlcNAc, GlcA(2SO4)β1,4GlcNAcα1,4GlcA, GlcNAcα1,4GlcA(2SO4)β1,4GlcNAc, IdoA(2SO4)α1,4GlcNAcα1,4GlcA, GlcNAcα1,4IdoA(2SO4)α1,4GlcNAc, GlcA(2SO4)β1,4GlcNSO3α1,4GlcA, GlcNSO3α1,4GlcA(2SO4)β1,4GlcNAc, IdoA(2SO4)α1,4GlcNSO3Hα1,4GlcA, GlcNSO3α1,4IdoA(2SO4)α1,4GlcNAc, GlcAβ1,4GlcNα1,4GlcA, GlcAβ1,4GlcNSO3α1,4GlcA, GlcNSO3α1,4GlcAβ1,4GlcNAc, IdoAα1,4GlcNSO3α1,4GlcA, GlcNSO3α1,4IdoAα1,4GlcNAc, GlcAβ1,4GlcNSO3(6SO4)α1,4GlcA, GlcNSO3(6SO4)α1,4GlcAβ1,4GlcNAc, IdoAα1,4GlcNSO3(6SO4)α1,4GlcA, GlcNSO3(6SO4α1,4IdoAα1,4GlcNAc, IdoA(2SO4)α1,4GlcNSO3(6SO4)α1,4GlcA, GlcNSO3(6SO4)α1,4IdoA(2SO4)α1,4GlcNAc, IdoAα1,4 GlcNSO3α1,4IdoA, GlcAβ1,3GlcNAcβ1,4GlcA, GlcNAcβ1,4GlcAβ1,3GlcNAc, IdoAα1,4GlcNSO3, IdoAα1,4GlcNSO3(6SO4), IdoA(2SO4)α1,4GlcNSO3, IdoA(2SO4)α1,4GlcNSO3(6SO4), IdoA(2SO4)α1,4GlcNSO3(3SO4), GlcAβ1,4GlcNSO3, GlcAβ1,4GlcNSO3(6SO4), GlcA(2SO4)β1,4GlcNAc, GlcA(2SO4)β1,4GlcNSO3(3SO4), GlcAβ1,4GlcNSO3(3,6SO4), and GlcAβ1,4GlcNSO3(3SO4).